Vivek Subbiah: Sharing the Key Advances in Oncology and Exciting Publications from ASCO25
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X:
“ASCO25 was absolutely incredible!
So many groundbreaking advances in oncology and exciting publications that are going to change patient care.
Sharing the key ones below.
Also added the 10+ simultaneous NEJM links.
What other important studies from ASCO 25 should be on everyone’s radar? Please add any I missed!
- Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
2. Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study.
3. Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.
4. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
5. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.
6. Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results.
7. Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients.
8. Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study.
9. Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.
10. Long-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the C-144-01 Study.
11. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer.
12. Vascular Normalization Augments the Anti-tumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors.
13. Clinical Validation of a Circulating Tumor DNA–Based Blood Test to Screen for Colorectal Cancer.
14. Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer – The REAL Randomized Clinical Trial.
15a. New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance JAMA Oncology C. Ola Landgren – Delighted to host a podcast with authors – adding link
15b. New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance JAMA Oncology.
16. Whole genome sequencing-powered ctDNA sequencing for breast cancer detection – Annals of Oncology.
NEJM exciting simultaneous publications ASCO. Link to tweetorial/ X-torial.”
More posts featuring Vivek Subbiah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023